BR112023021916A2 - Formas em estado sólido de (s)-n-(3-(2-(((r)-1- hidroxipropan-2-il)amino)-6-morfolinopiridin-4-il)-4- metilfenil)-3-(2,2,2-trifluoretil)pirrolidina-1-carboxamida e sais desta - Google Patents

Formas em estado sólido de (s)-n-(3-(2-(((r)-1- hidroxipropan-2-il)amino)-6-morfolinopiridin-4-il)-4- metilfenil)-3-(2,2,2-trifluoretil)pirrolidina-1-carboxamida e sais desta

Info

Publication number
BR112023021916A2
BR112023021916A2 BR112023021916A BR112023021916A BR112023021916A2 BR 112023021916 A2 BR112023021916 A2 BR 112023021916A2 BR 112023021916 A BR112023021916 A BR 112023021916A BR 112023021916 A BR112023021916 A BR 112023021916A BR 112023021916 A2 BR112023021916 A2 BR 112023021916A2
Authority
BR
Brazil
Prior art keywords
solid state
morpholinopyridin
hydroxypropan
carboxamide
pyrrolidine
Prior art date
Application number
BR112023021916A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Phimister
P Reddy Jayachandra
W Kaldor Stephen
Toufike Kanouni
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of BR112023021916A2 publication Critical patent/BR112023021916A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112023021916A 2021-04-23 2022-04-21 Formas em estado sólido de (s)-n-(3-(2-(((r)-1- hidroxipropan-2-il)amino)-6-morfolinopiridin-4-il)-4- metilfenil)-3-(2,2,2-trifluoretil)pirrolidina-1-carboxamida e sais desta BR112023021916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178752P 2021-04-23 2021-04-23
PCT/US2022/025815 WO2022226221A1 (en) 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof

Publications (1)

Publication Number Publication Date
BR112023021916A2 true BR112023021916A2 (pt) 2023-12-19

Family

ID=83723159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021916A BR112023021916A2 (pt) 2021-04-23 2022-04-21 Formas em estado sólido de (s)-n-(3-(2-(((r)-1- hidroxipropan-2-il)amino)-6-morfolinopiridin-4-il)-4- metilfenil)-3-(2,2,2-trifluoretil)pirrolidina-1-carboxamida e sais desta

Country Status (11)

Country Link
US (1) US20240208931A1 (enExample)
EP (1) EP4326255A4 (enExample)
JP (1) JP7825636B2 (enExample)
KR (1) KR20240000540A (enExample)
CN (1) CN117529313A (enExample)
AU (1) AU2022261159A1 (enExample)
BR (1) BR112023021916A2 (enExample)
CA (1) CA3216258A1 (enExample)
IL (1) IL307910A (enExample)
MX (1) MX2023012521A (enExample)
WO (1) WO2022226221A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
EP4326256A4 (en) 2021-04-23 2025-03-19 Pierre Fabre Medicament Treating cancer with a RAF inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
BR112021001406A2 (pt) * 2018-07-31 2021-04-27 AusCann Group Holdings Ltd composições farmacêuticas auto-emulsificantes sólidas
CN113874381A (zh) 2019-03-22 2021-12-31 金耐特生物制药公司 Raf激酶的抑制剂
AR118826A1 (es) * 2019-05-03 2021-11-03 Kinnate Biopharma Inc Inhibidores de cinasas raf
BR112022007612A2 (pt) * 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases

Also Published As

Publication number Publication date
EP4326255A1 (en) 2024-02-28
AU2022261159A1 (en) 2023-11-23
KR20240000540A (ko) 2024-01-02
TW202309018A (zh) 2023-03-01
US20240208931A1 (en) 2024-06-27
WO2022226221A1 (en) 2022-10-27
CN117529313A (zh) 2024-02-06
JP7825636B2 (ja) 2026-03-06
IL307910A (en) 2023-12-01
MX2023012521A (es) 2023-12-15
EP4326255A4 (en) 2025-03-12
JP2024517431A (ja) 2024-04-22
CA3216258A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
CL2021002963A1 (es) Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer
BRPI0306559B8 (pt) composição farmacêutica para aplicação oral para mesilato de etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-propiônico e seu processo de preparação
BRPI0513864A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
MX2022014444A (es) Sal de malato de n-(4-{[6,7-bis(metiloxi) quinolin-4-il] oxi}fenil)-n'-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
PE20190377A1 (es) Formulaciones de un inhibidor de lsd 1
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
BRPI0407139A (pt) Compostos de amida substituìda por tri(ciclo)
MX360289B (es) Composiciones de tapentadol.
BR0012804A (pt) Derivados de amina e amida como ligandos para o receptor de neuropeptìdeo y y5 útil no tratamento da obesidade e outros distúrbios
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
BRPI0409182A (pt) derivados de oxima e seu uso como agentes farmaceuticamente ativos
AR045317A1 (es) Forma cristalina de agonista dl receptor adrenergico b2
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0308814A (pt) Aminoácidos com afinidade para a proteìna-alfa2gama
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
BR0209518A (pt) Novos derivados arilheteroalquilamina
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
SA523441175B1 (ar) N-(2-(4- سيانو ثيازوليدين -3- يل)-2- أوكسو إيثيل)- كينولين -4- كربوكساميدات
AR053169A1 (es) Metabolitos de n-2 (cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil) -2-metil -4-pi rimidinil] amino]-5-tiazol carboxamidas
BRPI0608176A2 (pt) usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
BRPI0414781A (pt) aminoácidos com afinidade para a proteìna (alfa)2(delta)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PIERRE FABRE MEDICAMENT (FR)